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OBJECTIVE: This study aims to evaluate changes in
proteomic salivary profile of patients with oral mucosi-
tis after adjuvant cancer treatments.
MATERIALS AND METHODS: Samples were collected
from patients after adjuvant cancer therapies, and were
analyzed by means of SELDI/TOF. Patients were sepa-
rated in two groups: patients affected by mucositis
(MUCOSITIS) and patient without mucositis (NO
MUCOSITIS). All patients were divided in function of
the anticancer treatment: patients who had radiother-
apy (MUCOSITIS RADIO), had not radiotherapy
(MUCOSITIS NO RADIO), had chemotherapy (MUCO-
SITIS CHEMO), and those who had not chemotherapy
(MUCOSITIS NO CHEMO). Statistical evaluation PCA
(Principal Component Analysis) was conducted with the
software BIO-RAD Data ManagerTM (Version 3.5).
RESULTS: We found the increased peaks of 3443, 3487,
and 4135 m/z in MUCOSITIS group, while 6237 m/z was
reduced. These same peaks would the same modifica-
tions in MUCOSITIS RADIO, while in MUCOSITIS
CHEMIO are increased 3443 and 6237 m/z but 3487,
4135 m/z are reduced. These data were confirmed by
the PCA.
CONCLUSION: Anticancer therapy influenced the level
expression of many salivary biomarkers in mucositis
with a good significance. Therefore, 3443, 3487, 4135,
and 6237 m/z are good biomarker candidates of oral
mucositis.
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Introduction
Oral mucositis is the most severe complication of anti-
cancer therapies. It occurs in 40–85% of patients during
chemotherapy and radiotherapy but also in patients who
have undergone hematopoietic stem cell transplantation
(Stiff, 2001; Peterson et al, 2011).
Many studies have identiﬁed four developmental stages
of oral mucositis: an initial stage, in which inﬂammation
is triggered by a therapeutic agent; the epithelial stage, in
which the action of drug reduces the rate of cell division;
the ulceration stage, caused by the loss of the epithelial
component; and lastly, the healing stage (Sonis, 2004).
During radio and chemo therapy, smoking and alcohol
abuse, poor oral hygiene, burning mouth syndrome, surgi-
cal oral procedures, and pre-existing diseases of oral cav-
ity may be signiﬁcant risk factors; a severe mucositis can
lead to partial or complete interruption of radiotherapy
before completion of the treatment protocol with a conse-
quent worsened cancer prognosis (Al-Dasooqi et al, 2013;
Campos et al, 2014).
Some patient-related variables, such as age and gender,
may inﬂuence onset and severity of mucositis. It has been
noticed that the risk of developing mucositis is higher in
children than in adults (Cheng et al, 2001; Sonis and Fey,
2002). In subjects over 50 years old, the risk of develop-
ing severe and long-term mucositis is high because
reduced renal excretion may alter the elimination of
chemotherapeutic drugs (Raber-Durlacher et al, 2000).
In women, the risk of mucositis caused by 5-ﬂuorouracile
(McGuire, 2002), one of the most important chemothera-
peutic agents responsible of mucositis, is higher than in men
(Sloan et al, 2000, 2002). Moreover, incidence of mucositis
is higher in patients treated with continuous infusion 5-
ﬂuorouracil compared to those receiving intermittent intra-
venous administration (Hansen et al, 1996). The signs and
symptoms of mucositis are oral burning, oral pain, sponta-
neous bleeding, dysphagia, dysarthria, and odynophagia.
Furthermore, the loss of continuous oral barrier is a risk fac-
tor for secondary infections (i.e., bacterial, fungal, and viral
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infections) that could disseminate in neutropenic patients
(Steinmann et al, 2012). In particular, oral burning and pain
during swallowing determine worsening of the quality of
life in oncologic patients and, in severe cases, may also
force the patient to parenteral nutrition (Barber et al, 2007;
McGuire et al, 2013).
Nowadays, in clinical practice there are a number of
preventive and therapeutic measures for oral mucositis.
The use of local anesthetics and analgesics has been rec-
ommended by some authors (Sonis, 2009; Roopashri et al,
2011), to reduce pain, which is the most troublesome
component of oral mucositis, that negatively affects
patient’s quality of life. Application of benzydamine
hydrochloride, a non-steroidal anti-inﬂammatory with anal-
gesic, anesthetic, and antimicrobial properties for topical
use, has proven to be effective as it reduces the frequency
and severity of ulcerative lesions of the mouth and there-
fore reduces pain (Worthington et al, 2007).
Cryotherapy practice is commonly indicated for the
management of lesions caused by mucositis. Holding an
ice cube in the oral cavity for 5 min before chemotherapy
and for 30 min after causes local vasoconstriction and
hence reduces the amount of drug reaching the oral
mucosa, alleviating the symptoms of mucositis. This
method not only provides pain relief, but may also prevent
the development of new lesions (Peterson et al, 2013).
Helium-neon laser therapy, with low intensity laser, is
indicated as a pretreatment to reduce the severity of
mucositis in patients undergoing chemotherapy. However,
as this type of treatment requires costly equipment and
specialized operators, its use is often restricted to a limited
number of patients (Migliorati et al, 2013; Raber-Durla-
cher et al, 2013).
However, despite these therapies, used alone or in com-
bination with antimicrobials, aimed to prevent or reduce
the severity of oral mucositis, there are not evidence-based
protocols at the moment (Steinmann et al, 2012).
Many researchers are investigating the mechanism that
leads to the development of mucositis, and recently have
identiﬁed proinﬂammatory cytokines and matrix metallo-
proteinases as biomarkers of oral mucositis (Logan et al,
2007; Al-Dasooqi et al, 2010).
In order to prevent a possible outbreak and offer new
starting points to ﬁnd the most effective preventive treat-
ment and therapy, primary aim of this case control study
is to identify potential biomarkers of oral mucositis, evalu-
ating changes of the proteomic salivary proﬁle of patients
with oral mucositis after adjuvant cancer treatments
(chemo and/or radiotherapies).
Furthermore, we sought to understand the extent to
which radio- and chemo-therapeutic treatments affect the
changes in the expression levels of biomarkers, assessing
patients with both mucositis vs control.
The saliva is a good diagnostic ﬂuid (Bigler et al,
2002; Kaufman and Lamster, 2002; Streckfus and Bigler,
2002; Hu et al, 2007a,c), and its collection is easy and
non-invasive, contains a wide range of proteins, many of
which have been shown to be informative for the detec-
tion of oral (Li et al, 2004; Hu et al, 2007b, 2008; Bigler
et al, 2009; Park et al, 2009)and systemic diseases(Xiao
and Wong, 2010; Zhang et al, 2010a,b).
The technique that enables a rapid and high-throughput
detection of proteins and peptides directly from crude mix-
tures is SELDI-TOF-MS. This has been used in a number
of studies related to diagnostic screening, biomarkers dis-
covery in clinical proteomics researches.
For this reason, the study was developed, thanks to the
SELDI-TOF/MS (Surface Enhanced Laser Desorption
Ionization Time-of-Flight Mass Spectrometry) technology
with ProteinChip array (Bio-Rad, Hercules, CA, USA)
(Streckfus et al, 2006).
Salivary samples from patients with cancer who devel-
oped oral mucositis following radio- and chemotherapy,
and from patients who did not develop the disease, were
analyzed to identify different levels of expression of
potential biomarkers of oral mucositis.
Materials and methods
Patient population
In this study, 60 saliva samples from patients with several tumor types
were recruited, among which 30 patients suffered from oral mucositis
(mucositis) and 30 did not (no mucositis). All patients underwent multi-
ple cycles of chemotherapy and/or radiotherapy before saliva collection
(the medical records of all patients included in the study are shown in
Table 1).
The patients were grouped according to their treatment: subjects with
mucositis who underwent radiotherapy (Mucositis R+), patients with
mucositis who did not undergo radiotherapy (Mucositis R), subjects
who did not develop mucositis and have underwent radiotherapy (No
Mucositis R+), subjects who did not develop mucositis and did not
undergo radiotherapy (No Mucositis R), patients with mucositis who
underwent chemotherapy (Mucositis C+), and patients with mucositis
who did not undergo chemotherapy (Mucositis C) subjects who did not
develop mucositis and underwent chemotherapy (No Mucositis C+).
The main chemotherapeutic reagents given to patients were the fol-
lowing: 5-ﬂuorouracil, Herceptin (trastuzumab), and cisplatin.
Saliva collection and processing
Saliva samples were collected in the morning after an accurate washing
of the mouth with water. All patients abstained from food and beverages,
smoking, and oral hygiene for at least 2 h before the sample collection.
Saliva was produced spontaneously without any kind of stimulation and
was collected by spitting directly inside of a 50-ml sterile test-tube.
Before the sample collection, every patient signed a speciﬁc informed
Table 1 Medical records of all patients included in the study.
Mucositis No Mucositis
n % n %
Age (years)
Mean  s.d. 63  10.6 56.43  10.95
Range 34–90 30–83
Sex
Male 13 43.3 15 50
Female 17 56.7 15 50
Tumor sites 16 53.3 9 30
Head and neck 5 16.7 12 40
Breast 4 13.3 4 13.3
Lung 2 6.7 5 16.7
Prostate 2 6.7 0 0
Ovary 1 3.3 0 0
Anticancer therapy
Radiotherapy 12 40 6 20
No radiotherapy 18 60 24 80
Chemotherapy 27 90 30 100
No chemotherapy 3 10 0 0
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consent. The study has been approved by the ethical committee of the
Azienda Ospedaliera Universitaria della Seconda Universita di Napoli –
n. prot. 165 – 12 April, 2011.
Saliva collection was stored at 80°C for subsequent analysis.
Before the analysis, samples were gradually freeze thawed, and a
cocktail of protease inhibitors (104 mM AEBSF, 80 lM aprotinin, 4 mM
bestatin, 1.4 mM E-64, 2 mM leupeptin and 1.5 mM pepstatin A) in a
ratio of 1:1000 was added to each sample.
After a centrifugation of 50 min at 18 130 9g, the supernatant has
been aliquoted, proteins have been assayed according to Bradford’s
Method, and the supernatant has been stored at 80°C until use.
ProteinChip array preparation and SELDI-TOF analysis
All samples, appropriately pretreated, were analyzed in duplicate with
Q10 ProteinChipArray SELDI-TOF analysis.
Each ProteinChip was subjected to two consecutive washings with
200 ll of binding buffer (100 mM Tris–Hcl pH 8.8) followed by the
addition of the sample. Ten micrograms of salivary proteins were added
to DB3 denaturing buffer (9 M urea, 2% CHAPS and 100 mM DTT)
with ratio vol/vol 2:3, and subsequently diluted in binding buffer to reach
a ﬁnal volume of 150 ll. Each sample was, therefore, spotted in dupli-
cate on the surface of the ProteinChip and incubated for 30 min on the
orbital shaker under constant shaking at 250 rpm.
After incubation, washes were performed: ﬁrst, washes with 150 ll of
binding buffer, then a quick wash with 200 ll of Milli-Q water (Milli-
pore, Molsheim, France).
Finally, 1 ll of matrix composed of 50% saturated solution of synap-
tic acid and 50% ACN/0.1% TFA (50% ACN/0.5% TFA for CHCA)
was applied to each spot twice.
All chips were analyzed setting the instrument in the same condition,
according to the Protocol Machine (6000 nJ low energy laser, high
6000 nJ; matrix attenuation in 2500 Da, focus mass 10 000 Da; sample
rate 800 MHz, covering 25% of the surface area of the spot, acquired
mass range from 2500 to 25 000 m/z).
The proteomic proﬁles of all the samples were analyzed with the soft-
ware BIO-RAD Data ManagerTM (Version 3.5) to identify differentially
expressed mass peaks (clusters) in the two groups with a signiﬁcance of
P < 0.05.
For this study, we used only the mass peaks in the range between
2500 and 25 000 m/z with a signal-to-noise ratio higher than 5 S/N.
Principal Components Analysis (PCA)
The data sets’ proteins were also analyzed by PCA (principal components
analysis), a nonparametric statistical analysis method to extract the most
relevant information from large data sets. It is used in BIO-RAD Data
Table 2 Differently expressed mass peaks between MUCOSITIS group
and NO MUCOSITIS group.
m/z P-value ROC Trend Mucositis Fold change
3443 1.48E-04 0.733737564 Increased 3.6
3487 0.033147121 0.660238422 Increased 2.89
4135 0.057320016 0.631334477 Increased 1.9
5133 0.026813933 0.327615780 Reduced 1.87
6237 0.037 0.311324185 Reduced 3.07
6318 0.012 0.674603175 Reduced 2.29




Figure 1 List of the differently excreted mass peaks in MUCOSITIS compared to NO MUCOSITIS patients (a). Mass spectra, gel-view of 3443, 3487
and 4135 m/z (b). Down, respectively, its group box and whiskers plot indicating 0, 25th, 50th, 75th, and 100th percentiles for sample groups within a
cluster (c)
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ManagerTM software (Version 3.5) to visualize spectra in two and three-
dimensional graphs.
The principle of this analysis is brieﬂy summarized below.
Each of the mass peaks SELDI presents, both in repeated measure-
ments of the same sample and in different samples, a deviation between
the signal and the background noise (variance). Each of the peaks consid-
ered may present high variance in repeated measurements of the same
sample (low redundancy) or vice versa and maintains a low deviation
(high redundancy).
In the PCA, only the peaks that have, in the same sample, a high
redundancy are considered, to remove from the analysis the background
noise which is a confounding factor. As the analysis SELDI generates a
complex data set consisting of hundreds of mass peaks, it is necessary to
calculate the covariance or the degree of linear relationship between dif-
ferent variables (mass peaks). The groups of peaks with high correlation
are the principal components (PC). PCAs, groups of related mass peaks,
are the three main components (PC1, PC2, PC3).
Results
Differential peaks identiﬁed in mucositis and in absence
of mucositis (MUCOSITIS—NO MUCOSITIS)
From the cluster analysis conducted on the MUCOSITIS
group and NO MUCOSITIS group, we found seven peaks
of m/z that are differentially expressed (Mann–Whitney
test P ˂ 0.05).
In particular, in Table 2 are reported all values of m/z,
P-value, ROC, trend in mucositis, and fold changes, of
mass peaks that are differentially expressed between the
two groups: MUCOSITIS and NO MUCOSITIS.
As can be seen in Table 2, there are four peaks mass/
charge that are mostly expressed in the group MUCOSI-
TIS’s sample (1.9 ˂ fold change ˃ 3.6).
Whereas, Table 2 shows three m/z peaks that turned out
to be reduced in MUCOSITIS group (3.07 < fold
change > 1.87).
In particular, the expression level of peak 3443 m/z
seems to be noticeably increased (fold change 3.6) in the
samples from subjects affected by mucositis, compared to
those who received therapies and were not affected (Fig-
ure 1).
Peaks 3487 and 4135 m/z also have a higher expression
level (fold change, respectively, of 2.89 and 1.9) in
MUCOSITIS samples compared to NO MUCOSITIS sam-
ples (Figure 1).
Moreover, in Figure 2 the peak 6237 m/z is down-regu-
lated in mucositis group (fold change 3.07).
(b) (a)
(c)
Figure 2 List of the differently excreted mass peaks in MUCOSITIS compared to NO MUCOSITIS patients (a). Mass spectra, gel-view of 6237 m/z
(b). Corresponding box and whisker plot (c)
Table 3 Differently expressed mass peaks between MUCOSITIS RADIO
group and MUCOSITIS NO RADIO group.
m/z P-value ROC Trend Mucositis radio Fold change
3443 0.043 0.727273 Increased 2.14
3487 0.038 0.597403 Increased 1.25
4135 0.019 0.662338 Increased 2.13
4306 0.037 0.305195 Reduced 3.1
4472 0.043 0.272727 Reduced 1.44
4639 0.043 0.272727 Reduced 1.55
5227 0.049 0.75974 Increased 1.93
5672 0.031 0.532468 Increased 2.25
6237 0.04 0.532468 Increased 1.44
9804 0.049 0.24026 Reduced 2.41
Table 4 Differently expressed mass peaks between MUCOSITIS
CHEMIO group and MUCOSITIS NO CHEMO group.
m/z P-value ROC Trend Mucositis Chemo Fold change
3443 0.025564 0.424242 Increased 1.34
3487 0.038675 0.424242 Reduced 1.17
5329 0.086474 0.871212 Increased 2.1
5381 0.03103 0.727273 Increased 2.1
5785 0.021467 0.121212 Reduced 2.59
6237 0.004772 0.651515 Increased 2.98
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Differential peaks identiﬁed in mucositis patients who
underwent radiotherapy and those who did not
(MUCOSITIS RADIO—MUCOSITIS NO RADIO)
To verify a possible inﬂuence of radiotherapy on the onset
and development of oral mucositis in patients affected by
cancer, we also conducted the cluster’s analysis in the
group of patients who developed the mucositis and under-
went radiotherapy (MUCOSITIS RADIO) and those who
developed it, but did not undergo radiotherapy (MUCOSI-
TIS NO RADIO).
In MUCOSITIS RADIO group, we identiﬁed six mass
change peaks with increased level expression and four
mass change peaks with reduced level expression
(Table 3).
In fact, the expression level of the peak 3443 m/z
increased (fold change 2.14) in sample of subjects who
underwent radiotherapy and developed mucositis (MUCO-
SITIS RADIO) compared to those who did not undergo
radiotherapy (MUCOSITIS NO RADIO).
In the MUCOSITIS RADIO group, peak 3487 and
4135 m/z also have a higher level of expression (fold
change 1.25 and 2.13, respectively) compared to MUCO-
SITIS NO RADIO.
The peak 6237 m/z turned out to have a quite high level
of expression in the MUCOSITIS RADIO group (fold
change 1.44), and was less expressed in the MUCOSITIS
group.
Peaks difference in MUCOSITIS CHEMO and
MUCOSITIS NO CHEMO
As shown in Table 4, there are 4 peaks of mass-charge
that are highly expressed and 2 peaks whose levels are
reduced in the MUCOSITIS CHEMO group as well. In
particular, the expression level of the peak 3443 m/z
appears to be increased (fold change 1.34) in samples
from to subjects who underwent chemo therapy and devel-
oped mucositis (MUCOSITIS CHEMO) compared to
those who did not undergo chemo therapy (MUCOSITIS
NO CHEMO).
On the contrary, the peaks 3487 and 4135 m/z were
found to have a reduced level of expression (fold change
of 1.13 and 1.3, respectively) compared to MUCOSI-
TIS NO CHEMO.
The peak 6237 m/z turned out to be more expressed in
the MUCOSITIS CHEMO.
Cluster analysis in MUCOSITIS R+, MUCOSITIS R,
NO MUCOSITIS R+, NO MUCOSITIS R, MUCOSITIS
C, MUCOSITIS C+, NO MUCOSITIS C+
To conﬁrm the possibility that changes in expression
levels of the peaks 3443.98, 3487, 4135, and 6237 m/z
can be associated with cancer therapies, we analyzed
their performance in patients with mucositis who had
radiotherapy (MUCOSITIS R+), patients with mucositis




Figure 3 Graphic representations of cluster data in three different groups: MUCOSITIS R, MUCOSITIS R+, NO MUCOSITIS R+, NO MUCOSITIS
R. Group box and whiskers plot of peaks 3443 (a1) and 3487 (b1); group scatter plot displaying average group intensities as horizontal lines of peaks
3443 (a2) and 3487 (b2)
Oral Diseases
Expression of salivary biomarkers in oral mucosi
F Ardito et al
213
mucositis and radiotherapy (NO MUCOSITIS R+),
patients without mucositis and radiotherapy (NO
MUCOSITIS R), patients with mucositis who had not
chemotherapy (MUCOSITIS C), patients with mucosi-
tis who had undergone chemotherapy (MUCOSITIS
C+), and patients who had not mucositis and not
chemotherapy (NO MUCOSITIS C+).
From this analysis, we found that the expression of the
peaks 3443, 3487, and 4135 m/z increased in the MUCO-
SITIS R+ group more than the others, while the expres-
sion of the peak 6237 m/z is reduced in MUCOSITIS R+
compared to the other groups (Figures 3 and 4).
In regard to the possible combination with chemother-
apy, changes in expression levels of the peaks 3443 and
3487 m/z increased in MUCOSITIS C group, but their
level is almost similar to that of the MUCOSITIS C+
group, while the expression level of the peak 4135 m/z is
higher in MUCOSITIS C+ compared to the other two con-
ditions (NO MUCOSITIS C+ and MUCOSITIS C) (Fig-
ures 5 and 6).
However, the expression of the peak 6237 m/z seems to
lower in combination with chemotherapy (MUCOSITIS
C+) (Figure 6).
Principal Component Analysis (PCA)
We used the principal component analysis (PCA) to con-
ﬁrm the increase in expression of 3443, 3487, and 4135
m/z and decrease of 6235 m/z in MUCOSITIS compared
to NO MUCOSITIS as veriﬁcated in cluster statistics anal-
ysis (Figure 7).
In PCA, the two groups studied (MUCOSITIS and NO
MUCOSITIS) show a distribution potentially correlated
with antitumoral treatment because the samples of mucosi-
tis group are separate from no mucositis samples.
The net offset between two groups (Figure 8) conﬁrm
that the changes in expression of proteins is associated
with radiotherapy and chemotherapy treatment.
Discussion
The cytotoxic effects of antineoplastic drugs on tissues
with high turnover, such as oral epithelium, and local
effects of radiation on oral mucosa are principally respon-
sible of mucositis.
In the major part of case, it compromises seriously the
patient’s quality of life and may interfere with the man-
agement of the primary disease.
It is extremely important to prevent mucositis, or at least
treat it to reduce its severity and possible complications.
Currently, several clinical trials to identify possible pre-
ventive treatments and protocols of cure and various
molecular biological studies to investigate the mechanism
of onset and development have been conducting.
However, despite the application of these therapies,
alone or combined, there are not yet evidence protocols
established.
Therefore, more research is needed especially in the
biological ﬁeld, to contribute to the identiﬁcation of
biomarkers of oral mucositis that can provide a starting
point toward the study of the most effective treatments.
(c1) (d1)
(c2) (d2)
Figure 4 Graphic representations of cluster data in three different groups: MUCOSITIS R, MUCOSITIS R+, NO MUCOSITIS R+, NO MUCOSITIS
R. Group box and whiskers plot of peaks 4135 (c1) and 6237 m/z (d1); group scatter plot displaying average group intensities as horizontal lines of
peaks 4135 (c2) and 6237 m/z (d2)
Oral Diseases
Expression of salivary biomarkers in oral mucosi
F Ardito et al
214
Aiming at this, we studied 60 saliva samples from can-
cer patients, 30 of which developed mucositis as a conse-
quence of chemo- and/or radiotherapy (MUCOSITIS
group) and 30 did not develop mucositis (NO MUCOSI-
TIS).
All samples were acquired with Q10 ARRAY Pro-
teinChip SELDI-TOF analysis, and proteomic proﬁles of
all samples were analyzed with the software BIO-RAD
Data ManagerTM (Version 3.5) to identify mass peaks dif-
ferentially expressed (clusters) within two groups with a
signiﬁcance of P < 0.05.
In mucositis group, the analyzing cluster, we got 3
mass/charge peaks whose expression levels were up-regu-
lated.
In particular, the peaks 3443, 3487, and 4135 m/z were
up-regulated in mucositis, while the peak 6237 was down-
regulated.
In addition, we further classiﬁed the samples included
in the group mucositis in patients who got radio
(MUCOSITIS RADIO) and patients who did not get radio
(MUCOSITIS NO RADIO), in order to evaluate whether
the expression of these potential biomarkers was or was
not related to cancer treatment.
From this analysis, we identiﬁed 6 mass peaks charge
whose levels were increased in the MUCOSITIS
RADIO group, and 4 mass peaks charge whose levels
were reduced in the MUCOSITIS NO RADIO group.
Among them, we found peaks 3443, 3487, 4135, and
6237 m/z up-regulated in patients who have developed
the disease and obtained radio (MUCOSITIS RADIO)
compared with patients who get MUCOSITIS NO
RADIO.
The same variation of expression of the markers 3443,
3487, 4135 m/z (up-regulated), and 6237 (down-regulated)
in all patients with mucositis and especially in those who
got radiotherapy, encourages us to think that this kind of
treatment might inﬂuence selectively these proteins.
In addition, we conducted cluster analysis dividing the
patients with oral mucositis also in function of the
chemotherapeutic treatment.
Also in this case, the results were interesting. In fact, in
the MUCOSITIS CHEMO group emerged 4 peaks of
mass/charge that turn out to be more expressed and 2
peaks whose levels were lower than in the group of
patients with mucositis who did not undergo therapy
(MUCOSITIS NO CHEMO).
The peaks 3443 and 6237 m/z were increased in the
MUCOSITIS CHEMO and MUCOSITIS, the peaks 3487
and 4135 m/z had a reduced level of expression in this
group.
This leads us to infer that the peak 3443 may be a good
biomarker because it is set up in mucositis and especially
in those who develop the disease as a consequent of radio-
and/or chemotherapy.
Chemotherapy and radiotherapy have a different inﬂu-
ence on the performance of other proteins.
(a1) (b1)
(a2) (b2)
Figure 5 Graphic representations of cluster data in three different groups: MUCOSITIS C+, MUCOSITIS C, NO MUCOSITIS C+. Group box and
whiskers plot of peaks 3443 (a1) and 3487 (b1); group scatter plot displaying average group intensities as horizontal lines of peaks 3443 (a2) and 3487
(b2)
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In fact, radiation therapy promotes a higher level of
expression of biomarkers 3487 and 4135 m/z, while
chemotherapy reduces the expression.
The down-regulation of the peak 6237 m/z in all
patients with mucositis does not seem to be associated
with anticancer treatment. In fact, the fold change in the
MUCOSITIS RADIO and MUCOSITIS CHEMO are,
respectively, 1.44 and 2.98, while it was down-regulated
in MUCOSITIS group (fold change 3.07).
In Figure 3, it is possible to assess the trend of the peak
3443 m/z. Graphically, we see that the expression of this
biomarker is higher in the group MUCOSITIS R+, lower
in the MUCOSITIS R, and even lower in others. A high
level of expression in the MUCOSITIS NO RADIO group
suggests an increase in the expression of the marker asso-
ciated with the inﬂammatory process typical of mucositis,
but the expression increased more in people who develop
mucositis and obtain radiotherapy.
However, analyzing the Figure 5, we noted that the
levels of this same marker are higher in the MUCOSITIS
C group, compared to the MUCOSITIS C+ group and
above NO MUCOSITIS C+. Hence, it is surely clear
that the increased level of expression can be associated
with the inﬂammatory process characteristic of mucosi-
tis, but it is not possible to correlate it with chemother-
apy treatments also because in this case, the samples
available were few in number.
Instead, the trend of the 3487 peak appears to be signif-
icantly related to radiotherapy. In Figure 3, the expression
is greater in the MUCOSITIS R+ and lower in the NO
MUCOSITIS R+, but in the latter group, the level is
higher than in other groups where patients did not undergo
radiotherapy.
The assessment in relation to chemotherapy appears to
be not entirely reliable because of the scarcity of samples
available.
The expression of the peak 4135 m/z, as seen in Fig-
ure 4, results to be higher in the MUCOSITIS R+, com-
pared to other groups. Here too, while a high-level group
also, MUCOSITIS NO RADIO, suggests a variation of
the expression of the marker linked to the inﬂammatory
process typical of mucositis, expression increases when
the patient has made radio and mucositis (MUCOSITIS
R+).
Moreover, as seen in Figure 6, the peak 4135 m/z
seems to be associated univocally with patients who
have mucositis and had chemotherapy; the peak had an
increased expression in MUCOSITIS C+, but the
expression seems to be identical in the two other
groups.
If this ﬁgure will be conﬁrmed on a larger series of
patients, we could claim to have found a marker exclu-
sively linked to this condition. This would contribute sig-
niﬁcantly to the study of targeted therapies and preventing
mucositis in patients who have chemotherapy.
In Figure 4 is shown the marker 6237 m/z: Its expres-
sion in MUCOSITI R+ seems to be low compared to
others. This down-regulation of the protein appears to be
(c1) (d1)
(c2) (d2)
Figure 6 Graphic representations of cluster data in three different groups: MUCOSITIS C+, MUCOSITIS C, NO MUCOSITIS C+. Group box and
whiskers plot of peaks 4135 (c1) and 6237 m/z (d1); group scatter plot displaying average group intensities as horizontal lines of peaks 4135 (c2) and
6237 m/z (d2)
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associated with the inﬂammatory process typical of
mucositis and radiotherapy. In Figure 6, the peak MUCO-
SITIS C+ 6237 m/z is strongly down-regulated. Therefore,
it would be necessary to expand the series and have a
comparison with subjects not suffering from mucositis and
who did not have chemotherapy.
The data sets’ proteins were also analyzed by PCA
(principal components analysis), which conﬁrmed that
there is no correlation between MUCOSITIS and NO
MUCOSITIS groups, for peaks differentially expressed
(3443, 3487, 4135, 6237 m/z). Therefore, the particular
variation of these protein expressions might be associated
with one condition rather with another. In conclusion, it
would be necessary to deepen this study with a larger
number of patients using analytical techniques aimed at
identifying these potential biomarkers. Knowing they will
serve to plan a protocol for prevention and treatment of
oral mucositis.
Figure 7 Cluster statistics analysis. The
expression levels of peaks 3443, 3487, and
4135 m/z is increased in MUCOSITIS group,
while 6237 m/z is reduced in NO MUCOSITIS
group
Figure 8 Principal components analysis (PCA)
generated using biomarker candidates selected
following univariate statistical analysis. These
graphics explain the effective differentiation of
MUCOSITIS and NO MUCOSITIS samples
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